Netstreit (NYSE:NTST) Stock, Quote.Headers.trade-ideas

Netstreit

Netstreit Corp is structured as an umbrella partnership real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants.

Hand,Of,Man,Touching,Magnifying,Glass,Icon,Search,For,Find

Long Ideas

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CUBE

NTST

These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts

reit shutter

Real Estate

5 Retail REITs With The Best Relative Strength

Real,Estate,Market,Crash,Concept,With,Red,Homes,And,Graph

REIT

3 REITs Near 52-Week Lows Just Received An Analyst Downgrade

Netstreit Corp

Raymond James analyst Stephen Laws downgrades NexPoint Real Est Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) from Strong Buy to Market Perform.

Downgrades

NREF

Raymond James Downgrades NexPoint Real Est Finance to Market Perform

This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.

Biotech

Health Care

Financing

General

TLSA

Tiziana Life Sciences Announced The National Institutes Of Health Have Awarded A $4M Grant To Study Nasal Anti-CD3 For Alzheimer's Disease

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

ONCY

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Raymond James analyst Stephen Laws downgrades Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) from Outperform to Market Perform.

Raymond James Downgrades Lument Finance Trust to Market Perform

SLRN

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology

Raymond James analyst James Rollyson initiates coverage on Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announces Price Target of $14.

Initiation

Raymond James Initiates Coverage On Helix Energy Solns Gr with Strong Buy Rating, Announces Price Target of $14

<ul>
<li>In a Phase 1 in healthy subjects, EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF).</li>
<li>CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM demonstrated robust left ventricular outflow tract (LVOT) gradient reductions without meaningful changes in LVEF.</li>
<li>Company announced dosing of first patients in CIRRUS-HCM 28-day trial.</li>
</ul>

EWTX

Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy

BTIG analyst Jake Fuller upgrades DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) from Neutral to Buy and announces $155 price target.

Upgrades

DASH

BTIG Upgrades DoorDash to Buy, Announces $155 Price Target

EWCZ

European Wax Center Announced Several Strategic Commercial And Operational Updates As The Company Continues To Focus On Its Key Initiatives Of Attracting New Guests, Retaining First-time Guests And Winning Back Lapsed Guests

This platform is intended to enable Plug to access capital by leveraging its equipment asset base and to provide equipment financing solutions to Plug&#39;s customers to support equipment sales growth.&nbsp;
As a first step in this platform, Plug signed three separate sale and leaseback transactions equivalent to ~$44 million&nbsp;with GTL Leasing, a portfolio company of Antin Infrastructure Partners.
These transactions enable Plug to retain access to crucial hydrogen equipment while strengthening its financial position. The funds generated will be reinvested into Plug&#39;s core operations and focused on driving long-term growth and expansion initiatives.
&nbsp;
&nbsp;

PLUG

Plug Power Reveals Establishment Of An Equipment Leasing Platform And Is Targeting Over $150M In The Near To Mid-term

Offerings

VVOS

Vivos Therapeutics Announced A Registered Offering Of $4.3M Selling 1.36M Shares At $3.15 Per Share

In his role as CFO, Dobson will help EVgo solidify its path to profitability as it continues to expand its nationwide network.

Management

EVGO

EVgo Appoints Paul Dobson As CFO, Effective October 1, 2024

ACHL

Achilles Therapeutics Discontinued Its TIL-Based cNeT Program And Closed Phase 1/2A CHIRON and THETIS Trials, And It Will Refocus Its Strategy To Explore Further Engagement With Third Parties, The Company Has Engaged BofA Securities To Provide Strategic Financial Advice

Buybacks

AerCap Holdings Plans New $500M Share Repurchase Program, Which Will Run Through March 31, 2025

Piper Sandler analyst Adam Maeder initiates coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight rating and announces Price Target of $131.

Piper Sandler Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $131

Working together with NVIDIA, SLB will build and optimize models to the specific needs and requirements of the data-intensive energy industry, including subsurface exploration, production operations and data management.&nbsp;

NVDA

SLB, NVIDIA Partner To Develop Generative AI Solutions For The Energy Industry

Chinese EV maker Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is reportedly eyeing taking over Volkswagen brand Audi&#8216;s car plant in Vorst, a city in Brussels.
What Happened: A Nio delegation visited the Vorst plant in recent weeks and is working on a bid to submit to Audi parent Volkswagen by next Monday, <a href="https://www.tijd.be/ondernemen/auto/chinees-nio-kandidaat-overnemer-voor-audi-brussels-fabriek/10565046.html">reported</a> Belgian newspaper De Tijd. Belgium-based D&#8217;Ieteren is also interested in the plant, the report said.
Volkswagen has decided not to make any more vehicles at the plant after the last Q8 e-tron SUV rolls off the production line next year. Unless the German automaker finds a buyer, the plant will be closed, leaving 2,910 employees unemployed, the report said. 
Why It Matters: For Nio, having a plant in Europe will help it avoid the high tariffs being considered for EV imports from China. 
The European Commission is <a href="https://www.benzinga.com/news/24/09/40810974/us-ally-urges-eu-to-reconsider-tariffs-on-chinese-evs-we-dont-need-another-war">expected to propose </a>final tariffs of up to 35.3% on electric vehicles manufactured in China, in addition to the standard 10% car import duty applied by the EU.&nbsp;
The Chinese EV maker started<a href="https://www.benzinga.com/markets/equities/24/09/40925180/teslas-chinese-competitor-nio-begins-deliveries-of-new-es8-in-europe-amid-eu-tariff-concerns-rep"> delivering the ES8 SUV </a>to customers in Europe earlier this month. The vehicle is referred to as the EL8 in the geography due to an older lawsuit with Audi. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40933228/tesla-registrations-in-eu-take-a-hit-in-2024-as-ev-demand-slows-volkswagen-volvo-and-toyota-continue">Tesla Registrations In EU Take A Hit In 2024 As EV Demand Slows: Volkswagen, Volvo, And Toyota Continue To Gain Speed</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Media

Chinese EV Maker Nio Eyes Audi's Brussels Plant Amid European Expansion: Report

UBER

Darden Restaurants Inks Pact With Uber To Introduce On-Demand Delivery, with Olive Garden The First To Pilot

GOEV

Canoo Announced That The U.S. Customs And Border Protection Has Officially Approved Final Activation Of Canoo's Oklahoma City Operations As A Foreign-Trade Zone, Becoming One Of The Largest FTZs In The State Of Oklahoma

Bernstein analyst Aneesha Sherman maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Outperform and lowers the price target from $112 to $109.

Bernstein Maintains Outperform on Nike, Lowers Price Target to $109

NETSTREIT files for $300M at-the-market equity offering

2 'Under The Radar' REITs Up To 40% Undervalued

Wedbush Securities initiates coverage of 4 net lease REITs

Netstreit Has Become More Compelling (Rating Upgrade)

EPR Properties, NetSTREIT upgraded to Strong Buy at Raymond James

Netstreit: Agree Realty 2.0 Or Potential Takeover Target?

The latest update is out from NETSTREIT ( ($NTST) ). NETSTREIT Corp. has unveiled an investor presentation detailing their strategic financial stan...

NETSTREIT Reveals Strategic Financial Position and Growth Outlook

If I Was Retiring In 10-20 Years With 10 REITs - Part 3

Stifel Nicolaus analyst Simon Yarmak maintained a Buy rating on NETSTREIT (NTST – Research Report) today and set a price target of $19.50. The comp...

Stifel Nicolaus Sticks to Its Buy Rating for NETSTREIT (NTST)

Buried Treasures: 11 Dramatically Undervalued REITs

APLE

EPRT

NLCP

PLYM

VICI

Press Releases

NETSTREIT Corp. Announces Launch of Public Offering of Common Stock

NETSTREIT Corp. Announces Pricing of Upsized Forward Common Stock Offering

NETSTREIT Corp. Announces Closing of Forward Common Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

NETSTREIT Corp. Announces Dates for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

NETSTREIT Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

NETSTREIT Corp. Publishes Its Inaugural Corporate Responsibility Report

NETSTREIT Corp. Announces Dates for First Quarter 2024 Earnings Release and Conference Call

NETSTREIT Reports First Quarter 2024 Financial and Operating Results

NETSTREIT Corp. Announces Dates for Second Quarter 2024 Earnings Release and Conference Call

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Netstreit

Netstreit (NTST) Forecast

Netstreit (NYSE:NTST) Stock, Quote.Headers.trade-ideas